SALT LAKE CITY, Feb. 26, 2015 (GLOBE NEWSWIRE) -- Perseon Corporation (Nasdaq:PRSN) (Perseon or the Company), a leading provider of medical systems that utilize heat therapy to treat cancer, today announced the appointment of Jennifer R. Hoglin as Vice President of Global Marketing, effective February 17, 2015. Ms. Hoglin is an executive marketing professional with 20 years of experience in product, brand, and business development experience in primarily life sciences as well as multiple other industries.
Clint Carnell, CEO of Perseon, commented, "Jennifer is a consummate life sciences marketing executive and I'm thrilled to welcome her to our leadership team at Perseon. Her professional expertise, honed from two decades with early stage to multi-national companies, is specialized right in the key areas of focus for Perseon: branding, customer adoption, and peer-to-peer marketing. Jennifer's new role and the marketing acumen she brings will be paramount to Perseon's future as we execute our strategic plan for commercial success in microwave ablation."
Ms. Hoglin's career spans key leadership roles in go-to-market and commercialization strategy and development, most recently as Vice President of Marketing at Catheter Connections Inc., a manufacturer of infection control products. Formerly as Senior Director of Global Marketing at Edwards Lifesciences, she led integral marketing efforts involving product portfolio development and global professional education teams, programs, and tactics. Earlier she managed strategic marketing for Myriad Genetics Laboratories' Preventive Care Business, and she has held various positions with CR Bard and 3M. Ms. Hoglin holds an MBA from Washington University, St. Louis, MO and a BA from The Colorado College, Colorado Springs, CO.
Perseon Corporation, formerly BSD Medical Corporation, is a life sciences company that develops, manufactures, markets and services groundbreaking medical systems to treat cancer using heat therapy. Perseon's MicroThermX® microwave ablation system employs precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property and distributes its products in the United States, Europe and Asia.
Statements contained in this press release that are not historical facts, including statements relating to our intent to divest our hyperthermia business in Spring 2015, focus on microwave ablation to create stockholder value, comply with Nasdaq continued listing requirements, generate capital from a transaction related to our building and pursue other strategic plans are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. All forward-looking statements are subject to risks and uncertainties, including the risk that for a variety of reasons we may not be able to execute on our strategic plans, and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date on which such statements are made, and the Company undertakes no obligation to update such statements to reflect events or circumstances arising after such date, except as required by law.
CONTACT: Tricia Ross Financial Profiles 310-622-8226 email@example.com